Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsImmune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.
As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
1.
A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.
2.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
3.
Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.
4.
An Eye Surgeon's Unexpected Discovery of the "Before and After".
5.
Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL
1.
The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late
2.
Anemia in Older Adults: Causes, Clinical Impact, and Evidence-Based Management
3.
Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds
4.
Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment
5.
Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
5.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge